<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  1<BR>                   <BR>                   <BR>                  INDICATIONS AND USAGE<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Femara is an aromatase inhibitor indicated for: <BR>                        <BR>                           Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)<BR><BR>                           <BR>                           Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2)<BR><BR>                           <BR>                           First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer (1.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1.1<BR>                         <BR>                        Adjuvant Treatment of<BR>                         Early<BR>                         Breast Cancer<BR>                         <BR>                     <BR>                     <BR>                        Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1.2 Extended Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                     <BR>                        Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)]. <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        1.3 First and Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                     <BR>                        Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)]. <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>